This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Start Date01 Aug 2015

Sponsor / Collaborator

University of Kentucky

[+1]

100 Clinical Results associated with Phendimetrazine Tartrate

100 Translational Medicine associated with Phendimetrazine Tartrate

100 Patents (Medical) associated with Phendimetrazine Tartrate

505

Literatures (Medical) associated with Phendimetrazine Tartrate

02 Sep 2025·INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY

Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry

Author: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio

In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.

08 Aug 2025·MOLECULAR BIOLOGY REPORTS

Biocontrol potential of Pseudomonas fluorescens: Phenazine mediated antifungal activity against phytopathogens.

Article

Author: Muthu, Sakthivel ; Abdi, Gholamreza ; Duraisamy, Nallusamy ; Lakshmikanthan, Mythileeswari ; Krishnan, Kathiravan

BACKGROUND:

Fungal phytopathogens pose significant threats to plant health and agricultural productivity. Biocontrol agents like Pseudomonas fluorescens offer eco-friendly alternatives to chemical fungicides. In this study, P. fluorescens was isolated from the rhizosphere of Vanda wightii and assessed for its potential as a biocontrol agent against key fungal pathogens.

METHODS:

The antagonistic activity of P. fluorescens was tested against Botrytis cinerea, Colletotrichum gloeosporioides, Fusarium oxysporum, and Rhizoctonia solani using dual plate and cross-streak assays. Siderophore and hydrogen cyanide production were evaluated as possible biocontrol mechanisms. Growth conditions were optimized by varying glycerol, tryptone, pH, and temperature. Phenazine, the main antifungal metabolite, was extracted and characterized using FTIR, HPLC, NMR, and mass spectrometry. Antifungal kinetics and membrane permeability assays were also conducted.

RESULTS:

P. fluorescens exhibited strong antagonism, forming clear inhibition zones against all tested pathogens. Optimal growth occurred with 2% glycerol, 2% tryptone, pH 7, and 35 °C. The purified phenazine showed significant antifungal activity, with inhibition zones of 18.29 ± 0.05 mm to 25.90 ± 0.02 mm and a MIC of 2.0 µg/mL against C. gloeosporioides. FTIR and NMR confirmed aromatic and carbonyl groups; HPLC revealed a 20.25 min retention time; and mass spectrometry detected a molecular ion peak at m/z 180.75. Time-course assays showed reduced spore viability at 16 h, while membrane assays indicated nucleotide leakage.

CONCLUSIONS:

P. fluorescens and its phenazine metabolite demonstrate strong biocontrol potential. Future work should focus on bioreactor-scale production and mode-of-action studies for integrated disease management.

01 Aug 2025·Journal of Infection and Public Health

Gender-specific weight-control behaviors : Utilizing the Narcotics Information Management System and Community Health Survey in 2020

Article

Author: Han, Euna ; Oh, Kyung Sun

BACKGROUND:

The prevalence of obesity and weight management differ by gender in Korea. This study aims to examine these differences by analyzing the patterns of pharmacological prescriptions of narcotic appetite suppressants and non-pharmacological weight control methods across genders.

METHODS:

This study utilized two datasets: the Community Health Survey (CHS), representing non-pharmacological interventions on a national scale, and the Narcotics Information Management System (NIMS), detailing pharmacological practices for weight control. The CHS provided data on obesity, physical activity, nutrition information, and lifestyle behaviors (smoking, drinking, walking), while NIMS data encompassed the use of narcotic appetite suppressants for weight management. A comparative analysis of the two data sources was conducted.

RESULTS:

Obesity rates were higher among men in their 30 s (51.3 %) and 40 s (46.5 %), whereas women showed increased obesity in their 50 s (25.7 %) and 60 s (31.4 %). Weight control attempts were more prevalent among women, who were more likely to engage in nutritional interventions and pharmacological treatments, particularly opioid appetite suppressants. Over 60 % of these prescriptions were given to women in their 30 s and 40 s, with phendimetrazine and phentermine being the most commonly prescribed. In men, the use of narcotic appetite suppressants was positively associated with high levels of physical activity (β = 9.16, 95 % CI: 2.92-15.41), while in women, prescriptions were associated with favorable health behaviors (β = 11.63, 95 % CI: 3.54-19.73).

CONCLUSIONS:

It is vital to recommend gender- and age-specific weight control strategies, both non-pharmacological and pharmacological. To prevent misuse, societal consensus on the appropriate prescription of narcotic appetite suppressants is crucial.

News (Medical) associated with Phendimetrazine Tartrate

02 Oct 2024

·www.globenewswire.com

OrganOx metra® System Approved for Liver Transplantation in Canada

2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025. The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1 “We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.” The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2 About OrganOxOrganOx is a commercial stage organ technology company with a focus on the preservation of isolated organs, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for the liver, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Other applications, including in kidney transplantation, are in development. Learn more at www.organox.com. About OrganOx metra®OrganOx metra® is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ and enabling viability testing.1 metra® is commercially available in UK (UKCA: 772261), European Union (CE Mark: MDR 772263 and MDR 772678) and the United States (FDA Approved: P200035). ContactsInvestor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com Media:Emma YangHealth+Commerceemma@healthandcommerce.com References: Watson, C.J.E, Gaurav, R., Fear, C. et al. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation 106(12): 2391–2398 (2022) https://doi.org/10.1097/TP.0000000000004263Nasralla, D., Coussios, C.C., Mergental, H. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018). https://doi.org/10.1038/s41586-018-0047-9

Clinical Study

100 Deals associated with Phendimetrazine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02080	Phendimetrazine Tartrate	A08A	DB01579

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	ACERTIS PHARMACEUTICALS, LLC	16 Apr 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis